Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Jiang, H
Triple receptor profile GLP-1R, GIPR, and GCGR simultaneous engagement in research models Referenced in peer-reviewed literature on triple incretin receptor pharmacology Useful for comparative studies alongside single and dual agonist reference compounds Lyophilized format ensures stability and reproducibility across experimental runs Batch and lot identifiers on all labeling for full laboratory documentation compliance Research Background GLP3-R (Retatrutide) has been referenced in scientific literature as a GLP-1/GIP/glucagon receptor triple agonist
The Weight Regain Evidence Most patients regain 5070% of lost weight within 12 months of stopping without a structured maintenance plan Hunger and cravings typically return to pre-treatment levels within 24 weeks of stopping Metabolic improvements (blood sugar, blood pressure, lipids) also partially reverse after stopping Patients who built strong protein and exercise habits during treatment maintain significantly more of their weight loss 6
Do not discard it
doi:10.1210/jc.2010-0415 Behrooz HG, Tohidi M, Mehrabi Y, Behrooz EG, Tehranidoost M, Azizi F
